The European Haemophilia Consortium (EHC) is an international non-profit organisation that represents 45 national patients’ organisations of people with rare bleeding disorders from 27 Member States of the European Union (EU) and most Member States of the Council of Europe.

The EHC represents approximately 90,000 people diagnosed with a rare bleeding condition such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe. However, it is estimated that many more live with an undiagnosed rare bleeding disorder.

The EHC actively supports its National Member Organisations (NMOs) at national and European levels, and also helps NMOs to engage with each other, with the objectives of:

• Improving quality of life of people living with rare bleeding disorders,
• Improving diagnostic and treatment facilities,
• Ensuring adequate supply of – and access to – safe factor concentrates,
• Promoting patients’ rights and raising ethical issues,
• Following and influencing developments in European health policy,
• Understanding the status of haemophilia care in member countries through regular surveys,
• Stimulating research in all fields related to haemophilia and related rare bleeding disorders.

The EHC draws on the knowledge of patients, healthcare professionals, the scientific community, the European institutions and the pharmaceutical industry to share expertise within Europe. The EHC also collaborates closely with other European patient organisations to ensure a strong collective voice for people with rare bleeding disorders.

 

Recordings taken during previous EHC conferences are available below or can be seen on the EHC YouTube channel. www.ehc.eu

 

2018

 

EHC NOW! Key highlights and concepts from the 2018 European Conference on Rare Diseases and Orphan Products (ECRD 2018) as seen by EHC President Brian O’Mahony, EHC CEO Amanda Bok and EHC Steering Committee member Olivia Romero-Lux.

 

 

What makes the difference between living a high-quality life or one in pain and isolation? This video highlights the significance of the latest set of Wildbad Kreuth recommendations that are the basis of the 2017 Council of Europe Resolution on haemophilia care. Whether or not these recommendations are implemented by European Governments is what can equal the above mentioned difference in quality of life…

Link to the new Council of Europe Resolution: 

https://www.edqm.eu/en/news/haemophilia-new-standards-patient-care-council-europe-resolution

 

 

 

Experience the energy, memories, ideas and discussions of the participants of the EHC Youth Leadership Workshop 2018!

 

 

 

Bold, determined and taking action. We introduce to you the remaining members of the EHC Women and Bleeding Disorders Committee – Tatjana Markovic (Serbia), Naja Skouw-Rasmussen (Denmark) and Ana Pastor (Portugal). Ulla Hakkarainen (Finland) was unavailable at the time of the interview.

 

 

 

 

 

 

 

 

 

 

 

2017

Inhibitor Stories captures the realities of life that people with haemophilia and inhibitors in Europe face day-to-day. Differences in access to treatment means very different outcomes for these patients. See their stories….

Produced and directed by Goran Kapetanovich for the EHC

 

EHC Youth Debate 2017

The annual EHC Youth Debate shines a spotlight on the future leaders of haemophilia patient advocacy, pitting youth and passion against experience and expertise in discussions on controversial topics.

The EHC Youth Debate and production of this video was made possible by an unrestricted grant from Sobi

 

 

 

EHC Partners

Click on the link below to read more about EHC Partners:

EHC Partners

 

2016

Stefan Tasic, the participant of the EHC Youth Leadership Workshop 2016 explains why it was important for him to participate in this event and how it could be useful for other young people in the EHC community.

 

 

2014

 

 

Interview with Brian O’Mahony, Chief Executive of the Irish Haemophilia Society and the President of the European Haemophilia Consortium

 

 

 

 

 

2013